IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

Claims 1.-50. (canceled)

51. (currently amended) A compressed tablet comprising: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, filler/compression aid, lubricant, and solvent, wherein efavirenz is about 50% by weight of the total composition of the compressed tablet, the superdisintegrant has a concentration in the tablet between about 1% to about 5% by weight, and ~~The compressed tablet as recited in Claim 1, wherein~~ the superdisintegrant is croscarmellose sodium.

52. (previously presented) The compressed tablet as recited in Claim 51, wherein:

the solvent comprises water, ethanol or mixtures thereof;
the filler/disintegrant is microcrystalline cellulose;
the binder is hydroxypropyl cellulose;
the surfactant is sodium lauryl sulfate;
the filler/compression aid is lactose hydrous spray dried; and
the lubricant is magnesium stearate.

53. (previously presented) The compressed tablet as recited in Claim 52, wherein the efavirenz is crystalline.

54. (previously presented) The compressed tablet as recited in Claim 52, wherein the croscarmellose sodium is about 5% by weight of the total composition of the compressed tablet.

55. (currently amended) The compressed tablet as recited in Claim 51, ~~1,~~ comprising efavirenz, microcrystalline cellulose NF, hydroxypropyl cellulose LF NF, croscarmellose sodium, sodium lauryl sulfate, lactose hydrous spray dried (EG), and magnesium stearate (EG).

56. (previously presented) The compressed tablet, as recited in Claim 55, containing about 300 mg of efavirenz, about 120 mg microcrystalline cellulose NF, about

19.2 mg hydroxypropyl cellulose LF NF, about 30 mg croscarmellose sodium, about 6 mg sodium lauryl sulfate, about 118.8 mg lactose hydrous spray dried (EG), and about 6 mg magnesium stearate (EG).

57.-60. (canceled)

61. (currently amended) A compressed tablet comprising: efavirenz, filler/disintegrant, superdisintegrant, binder, surfactant, filler/compression aid, lubricant, and solvent; wherein efavirenz is about 50% by weight of the total composition of the compressed tablet, and the superdisintegrant has a concentration in the tablet between about 1% to about 5% by weight; and wherein the compressed tablet is prepared via wet granulation in which efavirenz, filler/disintegrant, superdisintegrant, binder, and surfactant are blended intragranularly, and filler/compression aid and lubricant are added extragranularly; and ~~The compressed tablet as recited in Claim 57,~~ wherein the superdisintegrant is croscarmellose sodium.

62. (previously presented) The compressed tablet as recited in Claim 61, wherein:

the solvent comprises water, ethanol or mixtures thereof;
the filler/disintegrant is microcrystalline cellulose;
the binder is hydroxypropyl cellulose;
the surfactant is sodium lauryl sulfate;
the filler/compression aid is lactose hydrous spray dried; and
the lubricant is magnesium stearate.

63. (previously presented) The compressed tablet as recited in Claim 62, wherein the efavirenz is crystalline.

64. (previously presented) The compressed tablet as recited in Claim 62, wherein the croscarmellose sodium is about 5% by weight of the total composition of the compressed tablet.

65. (previously presented) The compressed tablet as recited in Claim 52, wherein efavirenz is present in an amount of about 300 mg.

66. (previously presented) The compressed tablet as recited in Claim 52, wherein efavirenz is present in an amount of about 600 mg.

67. (previously presented) The compressed tablet as recited in Claim 62, wherein efavirenz is present in an amount of about 300 mg.

68. (previously presented) The compressed tablet as recited in Claim 62, wherein efavirenz is present in an amount of about 600 mg.